^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CDH3 inhibitor

    Related drugs:
    Associations

    News

    Trials
    10ms
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=220, Recruiting, Amgen | Trial completion date: Sep 2027 --> Feb 2028 | Trial primary completion date: Jan 2027 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    over1year
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial completion date: Jan 2027 --> Aug 2027 | Trial primary completion date: May 2026 --> Dec 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    almost2years
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial completion date: Oct 2026 --> Jan 2027 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    almost2years
    Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=260, Recruiting, Amgen | Trial primary completion date: Apr 2025 --> Feb 2026
    Trial primary completion date • Metastases
    |
    MSLN (Mesothelin) • CDH3 (Cadherin 3)
    |
    AMG 305
    3years
    A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • SOX2 • CDH3 (Cadherin 3) • ENG (Endoglin) • TRB (T Cell Receptor Beta Locus)
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    3years
    STEMVAC in Patients With Early Stage Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=33, Recruiting, University of Washington | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • LAG3 (Lymphocyte Activating 3) • CD69 (CD69 Molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • FOXP3 (Forkhead Box P3) • GATA3 (GATA binding protein 3) • TRB (T Cell Receptor Beta Locus)
    |
    HER-2 negative • HER-2 expression • PGR expression
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    over3years
    A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. (PubMed, Front Immunol)
    Cytokine peak concentrations and CRS grade appeared to positively correlate with C. Although the study was terminated due to limited antitumor activity, it provides important insights into understanding and managing immune-related adverse events resulting from this class of molecules. URL: https://clinicaltrials.gov/ct2/show/NCT02659631, ClinicalTrials.gov Identifier: NCT02659631.
    P1 data • Clinical Trial,Phase I • Journal
    |
    CDH3 (Cadherin 3)
    |
    PF-06671008
    almost4years
    Cadherin-3 is a novel oncogenic biomarker with prognostic value in glioblastoma. (PubMed, Mol Oncol)
    Concomitantly, high CDH3 expression is predictive of shorter overall survival of GBM patients in independent cohorts. Together, our results show that CDH3/P-cadherin expression is associated with aggressiveness features of GBM and poor patient prognosis, suggesting that it may be a novel therapeutic target for this deadly brain tumor.
    Journal
    |
    CDH3 (Cadherin 3)
    4years
    Placental-Cadherin, a biomarker for local immune status and poor prognosis among patients with tongue squamous cell carcinoma. (PubMed, Eur Arch Otorhinolaryngol)
    We identified CDH3 as a pan-cancer gene with potential prognostic and diagnostic significance in various cancers, particularly in TSCC, where it is tumorigenic.
    Clinical • Journal
    |
    CDH3 (Cadherin 3)
    4years
    The expression and prognostic relevance of CDH3 in tongue squamous cell carcinoma. (PubMed, APMIS)
    In contrast to previous report about the prognostic value of CDH3 in OSCC, we were not able to validate the result in TSCC.
    Journal
    |
    CDH3 (Cadherin 3)
    4years
    Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. (PubMed, Curr Probl Cancer)
    AXL was expressed especially in MFS and STLMS. Sarcoma subtypes express multiple target genes relevant for ADCs, SPEAR T-cells and CAR's, warranting further clinical validation and evaluation.
    Clinical • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • AXL (AXL Receptor Tyrosine Kinase) • TNFRSF8 (TNF Receptor Superfamily Member 8) • MSLN (Mesothelin) • CD70 (CD70 Molecule) • CDH3 (Cadherin 3) • LRRC1 (Leucine Rich Repeat Containing 1)
    |
    HER-2 overexpression • HER-2 expression • MSLN expression • CD70 expression
    4years
    A circular RNA derived from FAT atypical cadherin 3 promotes lung cancer progression via forming a regulatory loop with oncogenic ELAV like RNA binding protein 1. (PubMed, J Biochem)
    Moreover, circ-FAT3 expression in lung cancer tissues was strongly positively and negatively correlated with HuR and miR-136-5p expression, respectively. Overall, our data reveal the previously uncharacterized regulatory loop of circ-FAT3/miR-136-5p/HuR in lung cancer, and provide novel evidence for the importance of circRNA as a ceRNA in tumorigenesis.
    Journal
    |
    FAT3 (FAT Atypical Cadherin 3) • CDH3 (Cadherin 3) • ELAVL1 (ELAV Like RNA Binding Protein 1) • MIR136 (MicroRNA 136)